This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.theguardian.com/society/2018/oct/22/antimicrobial-antibiotic-resistance-must-be-policy-priority-for-uk-government-say-mps
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| Antimicrobial resistance must be policy priority, say MPs | Antimicrobial resistance must be policy priority, say MPs |
| (about 2 months later) | |
| Tackling antimicrobial resistance needs to become a top-five policy priority for the government in order to help prevent the virtual loss of modern medicine, MPs have said. | Tackling antimicrobial resistance needs to become a top-five policy priority for the government in order to help prevent the virtual loss of modern medicine, MPs have said. |
| A report by the health and social care committee said it wants to see “tangible progress” over the next six months to “reverse the worrying exodus” from research into antimicrobial resistance (AMR). | A report by the health and social care committee said it wants to see “tangible progress” over the next six months to “reverse the worrying exodus” from research into antimicrobial resistance (AMR). |
| Antimicrobial-resistant infections kill at least 50,000 people a year in Europe and the US alone, and 700,000 people globally. These figures are predicted to rise dramatically over the next 30 years, with the death toll estimated to be 10 million a year by 2050 – higher than from cancer and diabetes combined. | Antimicrobial-resistant infections kill at least 50,000 people a year in Europe and the US alone, and 700,000 people globally. These figures are predicted to rise dramatically over the next 30 years, with the death toll estimated to be 10 million a year by 2050 – higher than from cancer and diabetes combined. |
| Despite this, no new classes of antibiotics have been developed for decades. They are not seen as profitable by drug companies as new antibiotics are initially prescribed sparingly during their patent lives, rather than used as a first line treatment. | Despite this, no new classes of antibiotics have been developed for decades. They are not seen as profitable by drug companies as new antibiotics are initially prescribed sparingly during their patent lives, rather than used as a first line treatment. |
| The report says that while in developed health systems it is possible to access alternative second- or third-line treatments when patients develop a resistant infection, mortality rates and costs of treatment are likely to be approximately double for a drug-resistant infection, generating an estimated cost to the NHS of £180m a year. | The report says that while in developed health systems it is possible to access alternative second- or third-line treatments when patients develop a resistant infection, mortality rates and costs of treatment are likely to be approximately double for a drug-resistant infection, generating an estimated cost to the NHS of £180m a year. |
| Ways to step up the fight against global antimicrobial resistance | Letters | Ways to step up the fight against global antimicrobial resistance | Letters |
| It said options to address this market failure include changes to patent law and to the ways that pharmaceutical companies are reimbursed for new antimicrobial medicines. | It said options to address this market failure include changes to patent law and to the ways that pharmaceutical companies are reimbursed for new antimicrobial medicines. |
| Although in primary care, there has been a 13% reduction in the number of prescriptions for antibiotics in the past five years, there has been less progress in secondary care and prescribing levels in the UK are still around double that of the Netherlands, Sweden and the Baltic states. | Although in primary care, there has been a 13% reduction in the number of prescriptions for antibiotics in the past five years, there has been less progress in secondary care and prescribing levels in the UK are still around double that of the Netherlands, Sweden and the Baltic states. |
| The report said a reduction in clinically unnecessary secondary-care prescribing was clearly needed. It also outlined that digital health tools for clinicians and policymakers could dramatically help to reduce the threat of antimicrobial resistance, but there has been significant variation in the uptake of this. | The report said a reduction in clinically unnecessary secondary-care prescribing was clearly needed. It also outlined that digital health tools for clinicians and policymakers could dramatically help to reduce the threat of antimicrobial resistance, but there has been significant variation in the uptake of this. |
| It suggested a single organisation be given responsibility for coordinating this across the NHS, and ensuring prompt evidence-based prescribing of antimicrobials, as well as other medicines. | It suggested a single organisation be given responsibility for coordinating this across the NHS, and ensuring prompt evidence-based prescribing of antimicrobials, as well as other medicines. |
| Antimicrobial resistance: what you need to know | Antimicrobial resistance: what you need to know |
| The report said that, in terms of Brexit, the government must make a clear commitment that any future trade deals will require any meat and dairy produce imported into the UK to meet at least the same standards relating to antibiotic use that apply to meat and dairy products produced in the EU. | The report said that, in terms of Brexit, the government must make a clear commitment that any future trade deals will require any meat and dairy produce imported into the UK to meet at least the same standards relating to antibiotic use that apply to meat and dairy products produced in the EU. |
| The committee chair, Dr Sarah Wollaston, said: “In six months we want to see tangible progress on implementing practical policies to reverse the worrying exodus from AMR research and development, and both government and industry should play their part in tackling this issue.” | The committee chair, Dr Sarah Wollaston, said: “In six months we want to see tangible progress on implementing practical policies to reverse the worrying exodus from AMR research and development, and both government and industry should play their part in tackling this issue.” |
| Last month the committee heard that the problem had been a “top-five” issue under David Cameron’s government, but appeared to have become less important. | Last month the committee heard that the problem had been a “top-five” issue under David Cameron’s government, but appeared to have become less important. |
| Lord O’Neill, who led a major review on the topic, told the committee he was not aware of any current senior ministers raising the issue. | Lord O’Neill, who led a major review on the topic, told the committee he was not aware of any current senior ministers raising the issue. |
| A Department of Health and Social Care spokeswoman said: “The UK is a recognised global leader on AMR and we are committed to tackling the issue both at home and internationally. | A Department of Health and Social Care spokeswoman said: “The UK is a recognised global leader on AMR and we are committed to tackling the issue both at home and internationally. |
| “GPs already prescribe antibiotics 13% less than they did in 2013, we have invested record amounts in research and development, and we will set ourselves challenging ambitions for the next five years.” | “GPs already prescribe antibiotics 13% less than they did in 2013, we have invested record amounts in research and development, and we will set ourselves challenging ambitions for the next five years.” |
| Drug resistance | Drug resistance |
| Health | Health |
| Antibiotics | Antibiotics |
| news | news |
| Share on Facebook | Share on Facebook |
| Share on Twitter | Share on Twitter |
| Share via Email | Share via Email |
| Share on LinkedIn | Share on LinkedIn |
| Share on Pinterest | Share on Pinterest |
| Share on WhatsApp | Share on WhatsApp |
| Share on Messenger | Share on Messenger |
| Reuse this content | Reuse this content |